FDA Approves Durvalumab for Muscle Invasive Bladder Cancer By Ogkologos - May 2, 2025 573 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the NIAGARA study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide on Cancer Pain Management Now Available Also in French FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment MOST POPULAR Lung Cancer Trial of Osimertinib Draws Praise—and Some Criticism July 5, 2023 Bowel scope screening to stop in England January 14, 2021 Sacituzumab Govitecan Demonstrates Significant Improvement in PFS in Heavily Pretreated, Locally... September 5, 2022 Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell... July 15, 2025 Load more HOT NEWS DeFi Trial: Smart Design and Impressive Results For the Benefit of... Research with integrity – the importance of communication Bride Learns Sign Language, Surprises Groom’s Deaf Parents & Signs Her... Daughter And Her Terminally Ill Dad Go On Bucket List Adventures...
